Interleukin-2, Ipilimumab, and Anti-PD-1: Clinical Management and the Evolving Role of Immunotherapy for the Treatment of Patients With Metastatic Melanoma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Interleukin-2, Ipilimumab, and Anti-PD-1: Clinical Management and the Evolving Role of Immunotherapy for the Treatment of Patients With Metastatic Melanoma
Authors
Keywords
-
Journal
CANCER BIOLOGY & THERAPY
Volume -, Issue -, Pages 00-00
Publisher
Informa UK Limited
Online
2015-09-30
DOI
10.1080/15384047.2015.1095401
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).
- (2017) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).
- (2017) Mario Sznol et al. JOURNAL OF CLINICAL ONCOLOGY
- Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
- (2015) Michele Maio et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses
- (2015) Paul A. Beavis et al. Cancer Immunology Research
- A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
- (2015) Robert D. Leone et al. Computational and Structural Biotechnology Journal
- Early Administration of Infliximab for Severe Ipilimumab-Related Diarrhea in a Critically Ill Patient
- (2014) Steven P. Merrill et al. ANNALS OF PHARMACOTHERAPY
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Managing The Skin Toxicities From New Melanoma Drugs
- (2014) John C. Mavropoulos et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
- (2014) Mabel Ryder et al. ENDOCRINE-RELATED CANCER
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma
- (2014) B. Liao et al. NEURO-ONCOLOGY
- Ipilimumab in the treatment of metastatic melanoma: management of adverse events
- (2014) Giuseppina Della Vittoria Scarpati et al. OncoTargets and Therapy
- In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates
- (2014) C. Wang et al. Cancer Immunology Research
- Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma
- (2013) M. Maio et al. ANNALS OF ONCOLOGY
- Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)
- (2013) D. McDermott et al. ANNALS OF ONCOLOGY
- Clinical activity of ipilimumab for metastatic uveal melanoma
- (2013) Jason J. Luke et al. CANCER
- Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab
- (2013) Jeffrey S. Weber et al. CANCER
- Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma
- (2013) Michele Del Vecchio et al. EUROPEAN JOURNAL OF CANCER
- Hypophysitis Caused by Ipilimumab in Cancer Patients: Hormone Replacement or Immunosuppressive Therapy
- (2013) A. Lammert et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202)
- (2013) James L. Rubenstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab-induced acute severe colitis treated by infliximab
- (2013) Cecile Pagès et al. MELANOMA RESEARCH
- The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma
- (2013) Howard L. Kaufman et al. Nature Reviews Clinical Oncology
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma
- (2013) J. J. Luke et al. ONCOLOGIST
- Ipilimumab for Patients With Advanced Mucosal Melanoma
- (2013) M. A. Postow et al. ONCOLOGIST
- Ipilimumab and Its Toxicities: A Multidisciplinary Approach
- (2013) L. A. Fecher et al. ONCOLOGIST
- Anti-PD1 Following Ipilimumab for Mucosal Melanoma: Durable Tumor Response Associated with Severe Hypothyroidism and Rhabdomyolysis
- (2013) L. Min et al. Cancer Immunology Research
- Real-world impact of education: treating patients with ipilimumab in a community practice setting
- (2013) Blanca Ledezma et al. Cancer Management and Research
- Cellular Constituents of Immune Escape within the Tumor Microenvironment
- (2012) S. P. Kerkar et al. CANCER RESEARCH
- Development of an Fc-Enhanced Anti-B7-H3 Monoclonal Antibody with Potent Antitumor Activity
- (2012) D. Loo et al. CLINICAL CANCER RESEARCH
- CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
- (2012) P. A. Prieto et al. CLINICAL CANCER RESEARCH
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterizing the Clinical Benefit of Ipilimumab in Patients Who Progressed on High-dose IL-2
- (2012) Richard W. Joseph et al. JOURNAL OF IMMUNOTHERAPY
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Increasing Incidence of Melanoma Among Young Adults: An Epidemiological Study in Olmsted County, Minnesota
- (2012) Kurtis B. Reed et al. MAYO CLINIC PROCEEDINGS
- Cancer immunotherapy
- (2012) Thomas F. Gajewski Molecular Oncology
- Natural Innate and Adaptive Immunity to Cancer
- (2011) Matthew D. Vesely et al. Annual Review of Immunology
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Novel Management of Pruritus in Patients Treated With IL-2 for Metastatic Renal Cell Carcinoma and Malignant Melanoma
- (2010) Sung Ho Lee et al. JOURNAL OF IMMUNOTHERAPY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines
- (2008) F. O. Smith et al. CLINICAL CANCER RESEARCH
- Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy
- (2008) Karl S. Peggs et al. IMMUNOLOGICAL REVIEWS
- Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways
- (2008) Brian T. Fife et al. IMMUNOLOGICAL REVIEWS
- Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment
- (2008) Lawrence Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- The Biology of Interleukin-2
- (2007) Thomas R. Malek Annual Review of Immunology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search